Age over Fifty-Five Years at Diagnosis Increases Risk of Second Malignancies after Autologous Transplantation for Patients with Hodgkin Lymphoma

Sai Ravi Pingali, Rima M. Saliba, Paolo Anderlini, Chitra Hosing, Issa Khouri, Amin M. Alousi, Yago Nieto, Muzaffar H. Qazilbash, Richard Champlin, Uday R. Popat

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

The impact of age at diagnosis on outcomes of patients with Hodgkin lymphoma (HL) undergoing autologous hematopoietic transplantation (auto-HCT) is unclear. We retrospectively evaluated the impact of age on outcomes of 310 consecutive patients with relapsed/refractory HL who underwent auto-HCT between January 1996 and December 2010 with carmustine, etoposide, cytarabine, and melphalan conditioning therapy. Patients were stratified into ≤ 55 and >55-year-age groups based on age at diagnosis. At a median follow-up of 80 (range, 1 to 180) months, progression-free survival was similar between both age groups. However, age older than 55 years at diagnosis was associated with significantly poor overall survival with a hazard ratio [HR] of 2.3 (P =.003) from higher rate of second malignancies (HR, 3.8; P =.015) compared with patients 55 years or younger. In conclusion age > 55 years at diagnosis increases risk of second malignancies after auto-HCT.

Original languageEnglish (US)
Pages (from-to)1059-1063
Number of pages5
JournalBiology of Blood and Marrow Transplantation
Volume23
Issue number7
DOIs
StatePublished - Jul 2017

Keywords

  • Age
  • Autologous transplantation
  • Hodgkin lymphoma
  • Second malignancies

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint

Dive into the research topics of 'Age over Fifty-Five Years at Diagnosis Increases Risk of Second Malignancies after Autologous Transplantation for Patients with Hodgkin Lymphoma'. Together they form a unique fingerprint.

Cite this